Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 25;216(6):1234–1243. doi: 10.1084/jem.20181739

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Ritter and Greten

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 2. — Tumor immune statuses. Infiltration-excluded tumors (left) accumulate cytotoxic T lymphocytes (CTLs) around their margins, where they interact with Ly6c^loF4/80^hi TAMs or are impeded by cancer-associated fibroblasts (CAFs). Infiltration-inflamed tumors (right) show activated PD1⁺ CTLs in their core that express IFNγ and granzyme B (GrzB). They may form tertiary lymphoid structures and are generally associated with good prognosis and response to ICB. Therefore, therapies aim to promote this state. DC, dendritic cell; IDO, indoleamine (2,3)-dioxygenase; MSI, microsatellite instability.